MDACC Study No:2012-0434 ( NCT No: NCT01756677)
Title:A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Cytarabine; Lintuzumab-Ac225
Study Status:Closed
Study Description:The goal of the Phase 1 part of this study is to find the highest tolerable
dose of Lintuzumab-Ac225 that can be given with cytarabine to patients with AML.

The goal of the Phase 2 part of this study is to learn if Lintuzumab-Ac225 and
cytarabine can control AML. The safety of this drug combination will also be

Lintuzumab-Ac225 is designed to deliver radiation therapy directly inside
leukemia cells without giving any radiation to the surrounding normal cells

Cytarabine is designed to insert itself into DNA (genetic material) of cancer
cells and stop the DNA from repairing itself.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Cytarabine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Actinium Pharmaceuticals, Inc
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults